Active Not RecruitingNCT07396272
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression
Medication studyAges 18–75Sweden
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
- Listed locations
- LundSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 13, 2026
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 12
- Sponsor
- Daniel Lindqvist
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Sweden
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07396272
- Official title
Show the full official title
A Pilot, Open-label Phase II Trial of Adjunctive Treatment With Ketamine Hydrochloride Prolonged-Release Tablets (KET01) During the Initiation of Antidepressant Therapy in Major Depressive Disorder
Recruitment & locations
Not recruitingLund
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Daniel Lindqvist.
Does this study involve medication?
Yes. The study involves medication, including Treatment with Ketamine Hydrochloride Prolonged-Release Tablets.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
